Asia Pacific and Russia diagnostic study for EGFR testing - IGNITE
Study identifier:D7913C00074
ClinicalTrials.gov identifier:NCT01788163
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A diagnostic study to determine the prevalence of EGFR mutations in Asian and Russian patients with advanced NSCLC of Adenocarcinoma and Non-adenocarcinoma histologies
Medical condition
EGFR mutation status in aNSCLC patients (locally advanced and/or metastatic disease) with adenocarcinoma and non-adenocarcinoma histologies.
Phase
N/A
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
3500
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 27 Feb 2013
Primary Completion Date: 25 Aug 2014
Study Completion Date: 20 Jun 2016
Study design
Allocation: N/A
Endpoint Classification: N/A
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Verification:
Verified 01 Oct 2017 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Other: Locally advanced/metastatic NSCLC pats. Patients with locally advanced (stage IIIA/B) or metastatic NSCLC who have not received any local or systemic chemotherapy, and are not eligible for curative treatment (including surgery and chemoradiotherapy) | Genetic: EGFR mutation test EGFR mutation being tested in tissue and blood Other Name: Determination of EGFR mutation done at the Pathology lab |
Contacts
Investigators
Principal Investigator
Rose McCormack
AstraZeneca, PHB
